DataSheet1_Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study.docx
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may persist in patients with coronavirus disease 2019 (COVID-19) despite receiving standard care.
Methods: In this pilot study of hospitalized adult patients (≥18 years of age), with radiologically confirmed pneumonia who were SARS-CoV-2 positive for more than 28 days despite standard care, were assigned to receive standard of care (SOC, grp I) or leflunomide + SOC (grp 2). After 2 weeks, grp 1 and grp 2 patients who continued to be SARS-CoV-2-positive received leflunomide for 14 days while continuing SOC. The primary outcomes were the rate of and time to SARS-CoV-2 clearance and the 14-day and 30-day hospital discharge rate.
Results: 12 patients were enrolled in grp 1 and 15 patients were in grp 2. The 14 days SARS-CoV-2 viral clearance rate was 80.0% (12/15) for grp 2 patients receiving leflunomide vs. 16.7% for grp 1 patients (2/12) (p = 0.002). By day 14, the median time to SARS-CoV-2 clearance was 6.0 days (range 1–12, IQR 1–12) for grp 2 patients. In grp 1, two patients converted to viral negative on days 1 and 6 (p = 0.002). The 14-day discharge rate was 73.3% (11/15) for the grp 2 vs. 8.3% (1/12) for grp 1 (p = 0.001). The 30 days discharge rate was 100% (15/15) for the grp 2 vs. 66.7% (8/12) for grp 1. No severe adverse events or deaths were reported.
Conclusion: Leflunomide may improve the SARS-CoV-2 clearance rate and discharge rate in patients with refractory COVID-19. The tolerability of the 14–28 days course of treatment with leflunomide is acceptable. These preliminary observations need to be verified by a large sample size and randomized controlled trial.
History
References
- https://doi.org//10.1097/tp.0b013e3181e94106
- https://doi.org//10.1007/s40265-014-0212-x
- https://doi.org//10.1128/jvi.01737-09
- https://doi.org//10.1001/jamanetworkopen.2020.8857
- https://doi.org//10.1056/NEJMoa2001282
- https://doi.org//10.1111/j.1399-3062.2011.00682.x
- https://doi.org//10.7326/0003-4819-158-3-201302050-00583
- https://doi.org//10.1002/1529-0131(200109)44%3A9<1984%3A%3AAID-ART346>3.0.CO;2-B
- https://doi.org//10.1056/NEJMoa2007016
- https://doi.org//10.1111/nep.12948
- https://doi.org//10.1056/NEJMoa2021436
- https://doi.org//10.1097/tp.0b013e3182007be2
- https://doi.org//10.1101/2020.04.16.20065920
- https://doi.org//10.1186/s13073-018-0570-1
- https://doi.org//10.1002/art.1780381111
- https://doi.org//10.1159/000091251
- https://doi.org//10.16505/j.2095-0136.2020.0016
- https://doi.org//10.1101/2020.05.29.20114223
- https://doi.org//10.1001/jama.2020.6019
- https://doi.org//10.1097/00002030-200307250-00005
- https://doi.org//10.1136/bmj.c332
- https://doi.org//10.1159/000053979
- https://doi.org//10.1002/jmv.25946
- https://doi.org//10.1177/0961203308089408
- https://doi.org//10.1056/nejm200503173521125
- https://doi.org//10.1101/2020.03.11.983056
- https://doi.org//10.1016/0006-2952(96)00303-6